Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-1.77%
+1.65%
-2.19%
VALN
Valneva SE
$10.63
Login to see Valneva SE (VALN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Upgraded on attractively valued
Chart
$8.93 (+19.04%)
$6.08 (+74.84%)
$6.17 (+72.29%)
$5.89 (+80.48%)
VALN has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Low volume
High volatilty
VALN overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Reported a strong earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future
VALN Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
VALN Street view is extremely bullish and have negative views on the near-term outlook
Average key support and resistance price levels.
Login to displayVALN Earnings
The TTM reflects 12-month period, providing review of VALN financial performance.
The company financial health has moderately improved over the past year
Financial Score
What is VALN current stock price?
What are VALN stock strengths?
What risks are associated with VALN stock?
When is VALN next earnings report?
What is VALN market cap and volume?
What is VALN's current Stock IQ?
Should I buy VALN stock right now?
Is VALN a Strong Buy right now?
What does a 'Strong Buy' rating mean for VALN?
What does a 'Strong Sell' rating mean for VALN?
What factors influence VALN's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-1.77%
+1.65%
-2.19%
VALN
Valneva SE
Current Price
$10.63
Stock Insights
Strengths
Upgraded on attractively valued
Login to unlock Valneva SE (VALN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$8.93 (+19.04%)
$6.08 (+74.84%)
$6.17 (+72.29%)
$5.89 (+80.48%)
VALN Analysts Opinion
VALN Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Reported a strong earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future
VALN Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
VALN Street view is extremely bullish and have negative views on the near-term outlook
VALN has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Low volume
High volatilty
Average key support and resistance price levels.
Login to displayVALN Earnings
The TTM data reflects the most recent 12-month period, providing overview of VALN financial performance.
VALN Financial Health
The company financial health has moderately improved over the past year
Financial Score
VALN Latest Analysis
Valneva lowers 2025 financial outlook due to loss of Ixchiq vaccine marketing.
Mon Oct 6, 2025
Lyme Disease Market Growth Highlighted by Pipeline Advances and Expanding Patient Population | DelveInsight. Lyme Disease Market Growth Highlighted by Pipeline Advances and Expanding Patient Population |. DelveInsightAccording to DelveInsight'.s analysis the market for Lyme disease is anticipated to increase during the forecast period (2025–2034) owing to the launch of emerging therapies such as Valneva and Pfizer'.s VLA15 and Tarsus Pharmaceuticals'. TP-05 Moderna'.s mRNA-19
Wed Oct 1, 2025
Valneva Reports Strong Four-Year Antibody Persistence For Chikungunya Vaccine IXCHIQ . (RTTNews) - Valneva SE (VALN) announced positive four-year antibody persistence data following a single-dose vaccination with its chikungunya vaccine IXCHIQ. The results demonstrate robust and long-lasting immune responses across all age groups studied.
Tue Sep 30, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
VALN Stock trends
VALN Stock performance
VALN Stock analysis
VALN investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings